Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GENOMIC VALLEY BIOTECH LTD.

NSE : NABSE : 539206ISIN CODE : INE574D01010Industry : AgricultureHouse : Private

BSE25.582.08 (+8.85 %)

PREV CLOSE ( ) 23.50

OPEN PRICE ( ) 23.50

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 3192

TODAY'S LOW / HIGH ( )23.50 25.89

52 WK LOW / HIGH ( ) 21.0198.3

NSE

This Company is not listed in NSE

Select year

(Rs.in Million)

Particulars

Mar 2025

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Profit Before Tax

4.41

0.15

9.13

-4.21

-5.02

Adjustment

-0.02

0.00

-0.35

-2.57

1.89

Changes In working Capital

-3.27

-0.35

-16.57

-14.52

17.97

Cash Flow after changes in Working Capital

1.12

-0.20

-7.79

-21.29

14.85

Cash Flow from Operating Activities

0.27

-0.20

-7.79

-21.29

14.85

Cash Flow from Investing Activities

0.12

-0.15

15.22

36.68

-15.79

Cash Flow from Financing Activities

-7.05

-15.47

0.68

Net Cash Inflow / Outflow

0.39

-0.35

0.39

-0.09

-0.26

Opening Cash & Cash Equivalents

0.06

0.41

0.03

0.11

0.38

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

0.45

0.06

0.41

0.03

0.11